<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04916392</url>
  </required_header>
  <id_info>
    <org_study_id>UW20-589</org_study_id>
    <nct_id>NCT04916392</nct_id>
  </id_info>
  <brief_title>Observation Study of the Pharmacokinetics of Adductor Canal Block</brief_title>
  <official_title>An Observational Study of the Pharmacokinetics of Adductor Canal Block Using Liposomal Bupivacaine and Standard Bupivacaine in Total Knee Arthroplasty Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      With the aging of the population, osteoarthritis of knees and hips become major orthopedic&#xD;
      problems worldwide. Osteoarthritis of the knees and hips is associated with a significant&#xD;
      pain problem and functional disability. Total joints replacement is the ultimate surgical&#xD;
      procedure to deal with such problems. Multimodal analgesia, including periarticular local&#xD;
      infiltration of analgesia (LIA), regional nerve block using adductor canal block (ACB),&#xD;
      opioid and non-opioid have been shown to be effective in managing postoperative pain.&#xD;
      Regional nerve block using femoral nerve block or adductor canal block (ACB) is also a&#xD;
      well-established analgesic technique after total knee replacement. Standard bupivacaine (SB),&#xD;
      levobupivacaine, ropivacaine were used in ACB in these studies. Whether combining ACB with&#xD;
      periarticular LIA has the additional benefit of prolonging analgesia or with synergistic&#xD;
      effect remains controversial, because the number of RCTs conducted is not enough. Liposomal&#xD;
      bupivacaine (LB) may further prolong the analgesic effect of ACB, as the therapeutic levels&#xD;
      of bupivacaine are below the toxic range and sustained for 72 hours after injection. The&#xD;
      purpose of this study is to evaluate the safety and systemic levels of serum bupivacaine&#xD;
      following adductor canal block using LB 66.5mg and SB 50mg in patients undergoing TKA with&#xD;
      LIA over a 72-hour period. This also serves as a pilot study to determine the dose and timing&#xD;
      of blood taking for serum bupivacaine level of a previously IRB approved study - &quot;Comparing&#xD;
      the efficacy of combining periarticular local infiltration of analgesia and adductor canal&#xD;
      block using liposomal bupivacaine and standard bupivacaine- A prospective randomized&#xD;
      controlled trial&quot;.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After signing the consent form, participants will be assigned to one of the two groups.&#xD;
&#xD;
      LB group: LIA with ACB will be given using 5ml of 1.33% liposomal bupivacaine with 5ml of&#xD;
      0.9% normal saline.&#xD;
&#xD;
      SB group: LIA with ACB will be given using 10ml of 0.5% bupivacaine. Participants will&#xD;
      receive routine preoperative, intraoperative, and postoperative treatments like other&#xD;
      patients undergoing total knee replacement.&#xD;
&#xD;
      Blood will be collected during induction, at 1 hour, 2 hours, 4 hours, 8 hours, and 12 hours&#xD;
      after the performance of ACB through a designated 14-gauge cannula, and also at 24, 48, and&#xD;
      72 hours after the operation during routine blood taking.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time to peak concentration of serum bupivacaine</measure>
    <time_frame>72 hours after the operation</time_frame>
    <description>Serum bupivacaine will be quantified using High Performance Liquid Chromatography.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Toxicity, Drug</condition>
  <arm_group>
    <arm_group_label>liposomal bupivacaine</arm_group_label>
    <description>Nerve block will be preformed using 5ml of 1.33% liposomal bupivacaine with 5ml of 0.9% normal saline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard bupivacaine</arm_group_label>
    <description>Nerve block will be preformed using 10ml of 0.5% standard bupivacaine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal bupivacaine</intervention_name>
    <description>5ml of 1.33% liposomal bupivacaine with 5 ml of 0.9% normal saline will be given to treatment group.</description>
    <arm_group_label>liposomal bupivacaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>10ml of 0.5% bupivacaine will be given to control group.</description>
    <arm_group_label>standard bupivacaine</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients admitted for elective primary unilateral total knee replacement in Queen Mary&#xD;
        Hospital.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ASA I-III&#xD;
&#xD;
          -  Age 18-80 years old&#xD;
&#xD;
          -  Scheduled for elective primary unilateral total knee replacement&#xD;
&#xD;
          -  Chinese patients&#xD;
&#xD;
          -  BMI &lt; 40&#xD;
&#xD;
          -  Able to speak and understand Cantonese&#xD;
&#xD;
          -  Able to provide informed oral and written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Revision total knee replacement&#xD;
&#xD;
          -  Single-stage bilateral total knee replacement&#xD;
&#xD;
          -  Complex primary total knee replacement requiring the use of stem/augment/constrained&#xD;
             liner&#xD;
&#xD;
          -  Surgeries with significant intraoperative complications which may alter rehabilitation&#xD;
             protocol e.g. collateral ligament injury, fracture requiring fixation&#xD;
&#xD;
          -  Known allergy to opioids, local anaesthetic drugs, paracetamol, non-steroidal&#xD;
             anti-inflammatory drugs (NSAIDs) including COX-2 inhibitors&#xD;
&#xD;
          -  History of chronic pain other than chronic knee pain&#xD;
&#xD;
          -  History of immunosuppression&#xD;
&#xD;
          -  Daily use of glucocorticoids&#xD;
&#xD;
          -  Daily use of strong opioids (morphine, fentanyl, hydromorphone, ketobemidone,&#xD;
             methadone, nicomorphine, oxycodone, or meperidine)&#xD;
&#xD;
          -  History of severe heart disease (NYHA 2)&#xD;
&#xD;
          -  Alcohol or drug abuse&#xD;
&#xD;
          -  Impaired renal function, defined as preoperative serum creatinine level over 120&#xD;
             micromol/L&#xD;
&#xD;
          -  Pre-existing neurological or muscular disorders&#xD;
&#xD;
          -  Psychiatric illness or neurologic or psychiatric diseases potentially influencing pain&#xD;
             perception&#xD;
&#xD;
          -  Impaired or retarded mental state&#xD;
&#xD;
          -  Difficulties in using patient-controlled analgesia (PCA)&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Local infection&#xD;
&#xD;
          -  On immunosuppressants&#xD;
&#xD;
          -  High BMI (&gt;=40)&#xD;
&#xD;
          -  Patient refusal&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Timmy cw Chan, MBBS</last_name>
    <phone>22555679</phone>
    <email>timmychancw@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chi Wing Chan, MBBS</last_name>
      <phone>2255 5791</phone>
      <email>timmychancw@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 2, 2021</study_first_submitted>
  <study_first_submitted_qc>June 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2021</study_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Dr. Chan Chi-Wing</investigator_full_name>
    <investigator_title>Honorary Clinical Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

